HOME Research Insight Product Launches and Approvals is the Key Strategy Adopted by Leading Market Players to Foster their Growth in the Global Stem Cell Therapy Market



Product Launches and Approvals is the Key Strategy Adopted by Leading Market Players to Foster their Growth in the Global Stem Cell Therapy Market


The key players in the stem cell therapy market focused on various strategies such as product launches and approvals; expansions; and partnerships and agreements to enhance their presence in the global market. Product approvals, launches, and enhancements were the key strategies adopted by a majority of industry players to achieve growth in the stem cell therapy market. These strategies were majorly adopted by Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate SRL (Italy), and JCR Pharmaceuticals Co., Ltd. (Japan).

Osiris Therapeutics, Inc. (U.S.) dominated the global stem cell therapy market in 2015. The company’s product portfolio includes allogeneic stem cell-based products for musculoskeletal disorders (such as Bio4) and wounds and injuries application (such as Grafix, Stravix, and TruSkin). The company has a strong geographic presence in North America region. It primarily focuses on product development and commercialization to increase its revenue and strengthen its market position. The market has witnessed several product launches by Osiris Therapeutics in the last three years, such as Stravix (November 2015), TruSkin (November 2015), and Grafix (July 2014). This expanded the company’s stem cell-based product portfolio and strengthened its revenue base in the stem cell therapy market.

EDIPOST Co., Ltd. (South Korea) ranked second in the global stem cell therapy market in 2015. The company has a strong foothold in the stem cell therapy market. The company focuses on expanding its presence in the global stem cell therapy market by opting expansion strategy. In line with this, the company partnered with JingYuan Bio Ltd. (China), established a joint venture—OrLife Bio. (December 2014), entered into an agreement with Alkem Laboratories Ltd. (India) for commercialization of CARTISTEM (December 2013), and established MEDIPOST Hong Kong (its corporate office in Hong Kong) (January 2013). Additionally, the company focuses on organic growth strategy such as product development and commercialization to expand its product portfolio and strengthen its revenue base in the stem cell therapy market. In line with this strategy the company received the Orphan Drug designation for its product PNUEMOSTEM (December 2013) and launched its new stem cell therapy product for musculoskeletal disorder namely, CARTISTEM (January 2012).

Related Reports:

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports